# An Efficacy and Safety Study of GNR-068 (Ustekinumab Biosimilar) and Stelara® in the Treatment of Patients With Moderate to Severe Plaque Psoriasis

> **NCT06488664** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **AO GENERIUM** · enrollment: 422 (actual)

## Conditions studied

- Plaque Psoriasis

## Interventions

- **BIOLOGICAL:** GNR-068
- **BIOLOGICAL:** Stelara®

## Key facts

- **NCT ID:** NCT06488664
- **Lead sponsor:** AO GENERIUM
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-07-25
- **Primary completion:** 2025-04-30
- **Final completion:** 2025-09-30
- **Target enrollment:** 422 (ACTUAL)
- **Last updated:** 2025-07-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06488664

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06488664, "An Efficacy and Safety Study of GNR-068 (Ustekinumab Biosimilar) and Stelara® in the Treatment of Patients With Moderate to Severe Plaque Psoriasis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06488664. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*